Due to the small sample size of paired BRAF inhibitor samples from the BRAF inhibitor clinical trial, we could only identify a trend toward a correlation between CD40+ melanoma and patient survival, which warrants future trials to validate the role of CD40+ melanoma cells in treatment responses. This evidence concerns the gene CD40 and melanoma.